Apexian Pharmaceuticals
Indianapolis
About Apexian Pharmaceuticals
Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target. It was founded in 2005 and headquartered in Indianapolis, Indiana.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.9M
- Last round: Series Unknown (Aug 2021)
- Website: apexianpharma.com
- Phone: (317) 684-9106
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/apexian-pharmaceuticals-31683 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.